glp 1 after gallbladder removal Risks with GLP-1 Medications Navigating Semaglutide Use After Gallbladder

Several retrospective studies associated the drug class with lower glaucoma risk and reduced ocular hypertension incidence, while preclinical work demonstrated reduced retinal ganglion cell loss and optic nerve damage in experimental models. The experimental literature also points to inflammatory modulation, oxidative stress reduction and retinal ganglion cell survival pathways as possible mechanisms. Smaller studies evaluating IIH and DED reported reductions in intracranial pressure and improved ocular surface parameters, respectively, among treated patients. READ MORE: Blinding Disease-Weight Loss Drug Link: EMA Announces Start of Semaglutide Investigation The evidence base still has limits The review flagged recurring methodological constraints across the literature: reliance on retrospective EHR analyses and ICD-based coding, heterogeneous ocular endpoints, inconsistent imaging and limited longitudinal follow-up

FDA compliance and regulatory standing The FDA has substantially increased enforcement against telehealth GLP-1 marketing since September 2025

Consistent with this observation, a subset of entero-endocrine cells has been shown to co-express GIP and the proglucagon gene, suggesting concomitant secretion of both incretin hormones from such cells [45]

We offer a broad menu of testing from blood, saliva, urine & swab samples

Slowing Gastric Emptying One of the most important ways GLP-1 pills work for weight management is by slowing gastric emptying

Unger et al